Provided by Tiger Fintech (Singapore) Pte. Ltd.

BioVie Inc

1.08
+0.06005.88%
Post-market: 1.080.00000.00%19:51 EDT
Volume:155.53K
Turnover:165.69K
Market Cap:19.93M
PE:-0.35
High:1.10
Open:1.04
Low:1.03
Close:1.02
Loading ...

Company Profile

Company Name:
BioVie Inc
Exchange:
NASDAQ
Establishment Date:
2013
Employees:
14
Office Location:
680 West Nye Lane,Suite 204,Carson City,Nevada,United States
Zip Code:
89703
Fax:
- -
Introduction:
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Directors

Name
Position
Cuong Do
Director, President and Chief Executive Officer
Jim Lang
Chairman of the Board
Michael Sherman
Director
Richard Berman
Director
Robert Hariri
Director
Sigmund Rogich
Director
Steve Gorlin
Director

Shareholders

Name
Position
Cuong Do
Director, President and Chief Executive Officer
Joanne Wendy Kim
Chief Financial Officer
Joseph M. Palumbo
Chief Medical Officer